secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2026-02-04T23:59:59+00:00
Accession:  0000059478-26-000008
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly Q4 revenue up 43% to $19.3B; EPS $7.39 (+51%); FY2026 guidance $80-83B
----------------------------------------------------------------------------

- Q4 revenue $19.3B (+43% YoY); reported EPS $7.39 (+51%); non-GAAP EPS $7.54 (+42%), both incl. $0.52 acquired IPR&D.
- FY2026 guidance: revenue $80-83B; non-GAAP EPS $33.50-$35.00.
- FDA approved Kwikpen for tirzepatide; filed orforglipron for obesity in US, Japan, and EU.
- Positive Phase 3 results for Taltz+Zepbound combo in psoriatic arthritis and retatrutide for knee osteoarthritis.
- Agreement with U.S. government to expand access to obesity medicines for millions of Americans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947826000008/0000059478-26-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947826000008/lly-20260204.htm
  HTML page:      https://secwatch.observer/filing/0000059478-26-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer